Goldman Sachs analyst Andrea Tan maintained a Hold rating on Vor Biopharma (VOR – Research Report) today and set a price target of $4.00. The company’s shares closed last Tuesday at $4.15, close to its 52-week low of $4.01.
According to TipRanks.com, Tan has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -34.5% and a 0.0% success rate. Tan covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Codiak BioSciences, and Kodiak Sciences.
Vor Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $23.57.
Based on Vor Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.25 million. In comparison, last year the company had a GAAP net loss of $13.72 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.
Read More on VOR:
- Goldman Sachs Thinks Roivant Sciences’ Stock is Going to Recover
- Goldman Sachs Thinks Codiak BioSciences’ Stock is Going to Recover
- Relay Therapeutics (RLAY) Gets a Buy Rating from Goldman Sachs
- Alector (ALEC) Receives a Sell from Goldman Sachs
- Kodiak Sciences (KOD) Gets a Hold Rating from Goldman Sachs